ORY-4001
/ Oryzon
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
November 07, 2025
Earlier stage programs
(Oryzon Press Release)
- "ORY-4001, Oryzon’s highly selective histone deacetylase 6 (HDAC6) inhibitor nominated as a clinical candidate for the treatment of certain neurological diseases such as Charcot-Marie-Tooth disease (CMT), Amyotrophic Lateral Sclerosis (ALS) and others, continues to progress through IND enabling studies to prepare it for clinical studies."
Clinical • Amyotrophic Lateral Sclerosis • Genetic Disorders
1 to 1
Of
1
Go to page
1